Nuvelo to Host Conference Call on Thursday, September 25, 2008
September 24 2008 - 8:01PM
PR Newswire (US)
SAN CARLOS, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Nuvelo, Inc.
(NASDAQ:NUVO) today announced that it will hold a conference call
and webcast at 8:30 a.m. Eastern time (5:30 a.m. Pacific Time) on
Thursday, September 25, 2008 to discuss company news. To
participate in the conference call, please dial 866-854-8095 for
domestic callers and 706-634-8567 for international callers and
reference conference passcode 66253667. A telephone replay of the
conference call will be available through Wednesday, October 1,
2008. To access the replay, please dial 800-642-1687 for domestic
callers and 706-645-9291 for international callers and reference
conference passcode 66253667. This call is being webcast by
Thomson/CCBN. The webcast can be accessed via Nuvelo's website at
http://www.nuvelo.com/ and is also being distributed through the
Thomson StreetEvents Network. Individual investors can listen to
the call at http://www.earnings.com/, Thomson's individual investor
portal, powered by StreetEvents. Institutional investors can access
the call via Thomson StreetEvents (http://www.streetevents.com/), a
password-protected event management site. About Nuvelo Nuvelo, Inc.
is dedicated to improving the lives of patients through the
discovery, development and commercialization of novel drugs for
acute cardiovascular disease, cancer and other debilitating medical
conditions. Nuvelo's development pipeline includes NU172, a direct
thrombin inhibitor which has completed Phase 1 development for use
as a potential short-acting anticoagulant during medical or
surgical procedures; and NU206, a Wnt pathway modulator in Phase 1
development for the potential treatment of chemotherapy/radiation
therapy-induced mucositis and inflammatory bowel disease. In
addition, Nuvelo is pursuing research programs in leukemia and
lymphoma therapeutic antibodies and Wnt signaling pathway
therapeutics to further expand its pipeline and create additional
partnering and licensing opportunities. Information about Nuvelo is
available at our website at http://www.nuvelo.com/ or by phoning
650-517-8000. This press release contains "forward-looking
statements," which include statements regarding the timing,
progress and anticipated completion of Nuvelo's clinical stage and
research programs, and the potential benefits that patients may
experience from the use of our clinical stage compounds, which
statements are hereby identified as "forward-looking statements"
for purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. Such statements are based on our
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation,
uncertainties relating to drug discovery and the regulatory
approval process; clinical development processes; enrollment rates
for patients in our clinical trials; changes in relationships with
strategic partners and dependence upon strategic partners for the
performance of critical activities under collaborative agreements;
and the impact of competitive products and technological changes.
These and other factors are identified and described in more detail
in Nuvelo's filings with the SEC, including without limitation
Nuvelo's quarterly report on Form 10-Q for the quarter ended June
30, 2008 and subsequent filings. We disclaim any intent or
obligation to update these forward-looking statements. DATASOURCE:
Nuvelo, Inc. CONTACT: Nicole Foderaro, +1-415-215-5643, , or
Danielle Bertrand, +1-415-577-8258, , both of WeissComm Partners,
for Nuvelo, Inc. Web site: http://www.nuvelo.com/
Copyright
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jul 2023 to Jul 2024